REGENXBIO Inc., often abbreviated as RGNX, is a trusted biotechnology company making remarkable strides in gene therapy. Founded in 2009 and based in Rockville, Maryland, RGNX is a public company, traded on the NASDAQ under the ticker symbol "RGNX". The company has carved out a strong reputation in the field of gene therapy, thanks to its proprietary technology platform, NAV Technology Platform.
The NAV Technology Platform is an innovative system developed by REGENXBIO that is based on adeno-associated virus (AAV) vectors, specifically known for their potential in delivering therapeutic genes to the target cells. This advanced technology has separated REGENXBIO from other competitors by making gene therapy a practical and viable option for treatments of various diseases, including inherited genetic disorders and chronic diseases.
At the core of REGENXBIO's mission is the commitment to bringing transformative gene therapies to patients who need them. The company has numerous programs in various stages of clinical development that primarily target the central nervous system, metabolic disorders, and eye diseases among others.
One of the company's most promising products is RGX-314, a therapy developed for the one-time treatment of chronic retinal diseases, including wet age-related macular degeneration and diabetic retinopathy, without the need for regular anti-VEGF injections into the eye. ReNeuron, another significant product, is designed for the treatment of Mucopolysaccharidosis Type I (MPS I), a rare, genetic lysosomal storage disease.
Aside from its proprietary programs, REGENXBIO has also entered into multiple license agreements with leading biotechnology and pharmaceutical companies allowing them to use its NAV Technology Platform in their gene therapy programs. This includes licenses with AveXis, a Novartis Company, which led to the FDA approval of Zolgensma, a gene therapy for spinal muscular atrophy in pediatric patients.
REGENXBIO’s experienced leadership team under the helm of CEO Kenneth T. Mills is focused on innovative research and development, rigorous clinical studies, and maintaining strategic partnerships to continue improving and expanding their portfolio. The company claims its vision of leveraging the transformative potential of gene therapy is the driving force behind its efforts to develop life-changing treatments for patients suffering from serious, often life-threatening diseases. Undoubtedly, REGENXBIO Inc. underpins the advancement of gene therapy in modern medicine.